Early triple negative breast cancer: Are we getting better outcomes? A retrospective analysis from a single institution

Giacomo Barchiesi; Amelia McCartney; Chiara Biagioni; Olimpia Siclari; Lorenzo Rossi; Marta Pestrin; Angelo Di Leo; Laura Biganzoli

doi:10.1111/tbj.13437

Early triple negative breast cancer: Are we getting better outcomes? A retrospective analysis from a single institution

Giacomo Barchiesi
, Amelia McCartney
, Chiara Biagioni
, Olimpia Siclari
, Lorenzo Rossi
, Marta Pestrin
, Angelo Di Leo
, Laura Biganzoli

Research output: Contribution to journal › Article › Research › peer-review

1 Citation (Scopus)

Abstract

Overall survival (OS), disease-free survival (DFS), and distant recurrence-free interval (DRFI) were evaluated from 169 patients diagnosed with early triple negative breast cancer. Overall, 5 and 10 years OS, DFS, and DRFI were 77% and 65%; 60% and 46%; and 74% and 73%, respectively. Forty-seven patients did not receive chemotherapy. A separate analysis was performed excluding those patients. In this subgroup, 5- and 10-year OS, DFS, and DRFI were 86% and 77%; 68% and 54%, 77% both at 5 and 10 years. Prognosis is better than previously described; adjuvant chemotherapy should be offered to fit elderly patients if clinically warranted.

Original language	English
Pages (from-to)	1225-1229
Number of pages	5
Journal	The Breast Journal
Volume	25
Issue number	6
DOIs	https://doi.org/10.1111/tbj.13437
Publication status	Published - Nov 2019
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

breast cancer
elderly
outcome
prognosis
triple negative

Access to Document

10.1111/tbj.13437

Cite this

@article{f3e421ac949b41c39db39ed6f4810837,

title = "Early triple negative breast cancer: Are we getting better outcomes? A retrospective analysis from a single institution",

abstract = "Overall survival (OS), disease-free survival (DFS), and distant recurrence-free interval (DRFI) were evaluated from 169 patients diagnosed with early triple negative breast cancer. Overall, 5 and 10 years OS, DFS, and DRFI were 77\% and 65\%; 60\% and 46\%; and 74\% and 73\%, respectively. Forty-seven patients did not receive chemotherapy. A separate analysis was performed excluding those patients. In this subgroup, 5- and 10-year OS, DFS, and DRFI were 86\% and 77\%; 68\% and 54\%, 77\% both at 5 and 10 years. Prognosis is better than previously described; adjuvant chemotherapy should be offered to fit elderly patients if clinically warranted.",

keywords = "breast cancer, elderly, outcome, prognosis, triple negative",

author = "Giacomo Barchiesi and Amelia McCartney and Chiara Biagioni and Olimpia Siclari and Lorenzo Rossi and Marta Pestrin and \{Di Leo\}, Angelo and Laura Biganzoli",

note = "Publisher Copyright: {\textcopyright} 2019 Wiley Periodicals, Inc.",

year = "2019",

month = nov,

doi = "10.1111/tbj.13437",

language = "English",

volume = "25",

pages = "1225--1229",

journal = "The Breast Journal",

issn = "1075-122X",

publisher = "Wiley-Blackwell",

number = "6",

}

TY - JOUR

T1 - Early triple negative breast cancer

T2 - Are we getting better outcomes? A retrospective analysis from a single institution

AU - Barchiesi, Giacomo

AU - McCartney, Amelia

AU - Biagioni, Chiara

AU - Siclari, Olimpia

AU - Rossi, Lorenzo

AU - Pestrin, Marta

AU - Di Leo, Angelo

AU - Biganzoli, Laura

PY - 2019/11

Y1 - 2019/11

N2 - Overall survival (OS), disease-free survival (DFS), and distant recurrence-free interval (DRFI) were evaluated from 169 patients diagnosed with early triple negative breast cancer. Overall, 5 and 10 years OS, DFS, and DRFI were 77% and 65%; 60% and 46%; and 74% and 73%, respectively. Forty-seven patients did not receive chemotherapy. A separate analysis was performed excluding those patients. In this subgroup, 5- and 10-year OS, DFS, and DRFI were 86% and 77%; 68% and 54%, 77% both at 5 and 10 years. Prognosis is better than previously described; adjuvant chemotherapy should be offered to fit elderly patients if clinically warranted.

AB - Overall survival (OS), disease-free survival (DFS), and distant recurrence-free interval (DRFI) were evaluated from 169 patients diagnosed with early triple negative breast cancer. Overall, 5 and 10 years OS, DFS, and DRFI were 77% and 65%; 60% and 46%; and 74% and 73%, respectively. Forty-seven patients did not receive chemotherapy. A separate analysis was performed excluding those patients. In this subgroup, 5- and 10-year OS, DFS, and DRFI were 86% and 77%; 68% and 54%, 77% both at 5 and 10 years. Prognosis is better than previously described; adjuvant chemotherapy should be offered to fit elderly patients if clinically warranted.

KW - breast cancer

KW - elderly

KW - outcome

KW - prognosis

KW - triple negative

UR - https://www.scopus.com/pages/publications/85069832255

U2 - 10.1111/tbj.13437

DO - 10.1111/tbj.13437

M3 - Article

C2 - 31310384

AN - SCOPUS:85069832255

SN - 1075-122X

VL - 25

SP - 1225

EP - 1229

JO - The Breast Journal

JF - The Breast Journal

IS - 6

ER -

Early triple negative breast cancer: Are we getting better outcomes? A retrospective analysis from a single institution

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Cite this